• Publications
  • Influence
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
TLDR
The 2010 European League against Rheumatism recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and b DMARDs, respectively) have been updated and are intended to improve outcome in patients with RA. Expand
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
TLDR
Recommendations are intended to inform rheumatologists, patients and other stakeholders about a European consensus on the management of RA with DMARDs and GCs as well as strategies to reach optimal outcomes of RA based on evidence and expert opinion. Expand
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
TLDR
Infliximab was well-tolerated; withdrawals for adverse events as well as the occurrence of serious adverse events or serious infections did not exceed those in the placebo group. Expand
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
TLDR
Multiple infusions of cA2 were effective and well tolerated, with the best results occurring at 3 and 10 mg/kg either alone or in combination with MTX in approximately 60% of patients with active RA despite therapy with low-dose MTX. Expand
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
TLDR
The anti-CCP ELISA might be very useful for diagnostic and therapeutic strategies in RA of recent onset and appears to be highly specific for RA, using prevalent RA and non-RA sera. Expand
Treating rheumatoid arthritis to target: recommendations of an international task force
TLDR
The 10 recommendations are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA based on evidence and expert opinion. Expand
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with
TLDR
Combination therapy with adalimumab plus MTX was significantly superior to either MTX alone or ad alimumab alone in improving signs and symptoms of disease, inhibiting radiographic progression, and effecting clinical remission in patients with early, aggressive rheumatoid arthritis. Expand
How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis.
TLDR
A clinical prediction model was developed with an excellent ability to discriminate, at the first visit, between 3 forms of arthritis outcome, and validation in other early arthritis clinics is necessary. Expand
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
TLDR
The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA. Expand
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis.
TLDR
In vivo administration of anti-TNF-alpha Ab results in the rapid down-regulation of a spectrum of cytokines, cytokine inhibitors, and acute-phase proteins, consistent with the concept of a cytokine-dependent cytokine cascade. Expand
...
1
2
3
4
5
...